A guide to dosing in the treatment of cervical dystonia and blepharospasm with Xeomin ®: A new botulinum neurotoxin A

Fernando L. Pagan; Andrew Harrison

doi:10.1016/j.parkreldis.2012.02.008

A guide to dosing in the treatment of cervical dystonia and blepharospasm with Xeomin ^®: A new botulinum neurotoxin A

Fernando L. Pagan, Andrew Harrison

Ophthalmology & Visual Neurosciences

Research output: Contribution to journal › Review article › peer-review

10 Scopus citations

Abstract

Xeomin ^® (incobotulinumtoxinA; Merz Pharmaceuticals, Frankfurt am Main, Germany) was first introduced in Germany for movement disorders in 2005. In 2010, it was approved for use in the United States by the FDA for the treatment of cervical dystonia (CD) and blepharospasm. It is a unique botulinum type A formulation free of any complexing proteins and contains only the pure 150 kD neurotoxin. Thus, the formation of neutralizing antibodies is not induced even after long-term treatment. The purpose of this report is to review the safety profile and dosing schedule for Xeomin for the treatment of CD and blepharospasm. The recommended dose for patients with CD is 120 U/treatment, with administration intervals normally between 3 and 6 months. However, clinical studies have found Xeomin to be safe and effective at doses up to 400 U in both previously treated and treatment-naïve patients. The recommended starting dose in patients with blepharospasm is 2.5-5.0 U/injection site. Patients can be switched using a 1:1 conversion ratio from Botox ^® (onabotulinumtoxinA, Allergen Inc., Irvine, CA, USA) to Xeomin without any loss of efficacy or safety concerns. Xeomin does not differ from Botox in terms of its potency, onset, diffusion profile, or duration and waning of effect. It is the only botulinum treatment that is stable for up to 3 years at room temperature. Xeomin offers a new and important treatment option for movement disorders.

Original language	English (US)
Pages (from-to)	441-445
Number of pages	5
Journal	Parkinsonism and Related Disorders
Volume	18
Issue number	5
DOIs	https://doi.org/10.1016/j.parkreldis.2012.02.008
State	Published - Jun 2012

Bibliographical note

Funding Information:
This project was supported, in part, by an unrestricted grant from Research to Prevent Blindness and the Lions of Minnesota . This project was also supported by Merz Pharmaceuticals . Editorial support was provided by The Curry Rockefeller Group, LLC, Tarrytown, NY, which was supported by Merz Pharmaceuticals. Dr Pagan has received research grants from Medtronic , Soltice Neuroscience , and Teva Neuroscience ; has been a consultant and/or speaker for Allergan, Boehringer Ingelheim, GlaxoSmithKlein, Ipsen, Medtronic, Novartis, Soltice Neuroscience, and Teva Neuroscience; and served on an advisory panel for Merz Pharmaceuticals. Dr Harrison is a paid consultant for Merz Pharmaceuticals.

Keywords

Antibodies
Complexing proteins
Formulation
Hemagglutinins
Movement disorders
Safety

Access

10.1016/j.parkreldis.2012.02.008

OpenUrl availability

Full text

Cite this

@article{7987c28e2963437da5808bc852c48b35,

title = "A guide to dosing in the treatment of cervical dystonia and blepharospasm with Xeomin {\textregistered}: A new botulinum neurotoxin A",

abstract = "Xeomin {\textregistered} (incobotulinumtoxinA; Merz Pharmaceuticals, Frankfurt am Main, Germany) was first introduced in Germany for movement disorders in 2005. In 2010, it was approved for use in the United States by the FDA for the treatment of cervical dystonia (CD) and blepharospasm. It is a unique botulinum type A formulation free of any complexing proteins and contains only the pure 150 kD neurotoxin. Thus, the formation of neutralizing antibodies is not induced even after long-term treatment. The purpose of this report is to review the safety profile and dosing schedule for Xeomin for the treatment of CD and blepharospasm. The recommended dose for patients with CD is 120 U/treatment, with administration intervals normally between 3 and 6 months. However, clinical studies have found Xeomin to be safe and effective at doses up to 400 U in both previously treated and treatment-na{\"i}ve patients. The recommended starting dose in patients with blepharospasm is 2.5-5.0 U/injection site. Patients can be switched using a 1:1 conversion ratio from Botox {\textregistered} (onabotulinumtoxinA, Allergen Inc., Irvine, CA, USA) to Xeomin without any loss of efficacy or safety concerns. Xeomin does not differ from Botox in terms of its potency, onset, diffusion profile, or duration and waning of effect. It is the only botulinum treatment that is stable for up to 3 years at room temperature. Xeomin offers a new and important treatment option for movement disorders.",

keywords = "Antibodies, Complexing proteins, Formulation, Hemagglutinins, Movement disorders, Safety",

author = "Pagan, {Fernando L.} and Andrew Harrison",

note = "Funding Information: This project was supported, in part, by an unrestricted grant from Research to Prevent Blindness and the Lions of Minnesota . This project was also supported by Merz Pharmaceuticals . Editorial support was provided by The Curry Rockefeller Group, LLC, Tarrytown, NY, which was supported by Merz Pharmaceuticals. Dr Pagan has received research grants from Medtronic , Soltice Neuroscience , and Teva Neuroscience ; has been a consultant and/or speaker for Allergan, Boehringer Ingelheim, GlaxoSmithKlein, Ipsen, Medtronic, Novartis, Soltice Neuroscience, and Teva Neuroscience; and served on an advisory panel for Merz Pharmaceuticals. Dr Harrison is a paid consultant for Merz Pharmaceuticals.",

year = "2012",

month = jun,

doi = "10.1016/j.parkreldis.2012.02.008",

language = "English (US)",

volume = "18",

pages = "441--445",

journal = "Parkinsonism and Related Disorders",

issn = "1353-8020",

publisher = "Elsevier BV",

number = "5",

}

TY - JOUR

T1 - A guide to dosing in the treatment of cervical dystonia and blepharospasm with Xeomin ®

T2 - A new botulinum neurotoxin A

AU - Pagan, Fernando L.

AU - Harrison, Andrew

N1 - Funding Information: This project was supported, in part, by an unrestricted grant from Research to Prevent Blindness and the Lions of Minnesota . This project was also supported by Merz Pharmaceuticals . Editorial support was provided by The Curry Rockefeller Group, LLC, Tarrytown, NY, which was supported by Merz Pharmaceuticals. Dr Pagan has received research grants from Medtronic , Soltice Neuroscience , and Teva Neuroscience ; has been a consultant and/or speaker for Allergan, Boehringer Ingelheim, GlaxoSmithKlein, Ipsen, Medtronic, Novartis, Soltice Neuroscience, and Teva Neuroscience; and served on an advisory panel for Merz Pharmaceuticals. Dr Harrison is a paid consultant for Merz Pharmaceuticals.

PY - 2012/6

Y1 - 2012/6

N2 - Xeomin ® (incobotulinumtoxinA; Merz Pharmaceuticals, Frankfurt am Main, Germany) was first introduced in Germany for movement disorders in 2005. In 2010, it was approved for use in the United States by the FDA for the treatment of cervical dystonia (CD) and blepharospasm. It is a unique botulinum type A formulation free of any complexing proteins and contains only the pure 150 kD neurotoxin. Thus, the formation of neutralizing antibodies is not induced even after long-term treatment. The purpose of this report is to review the safety profile and dosing schedule for Xeomin for the treatment of CD and blepharospasm. The recommended dose for patients with CD is 120 U/treatment, with administration intervals normally between 3 and 6 months. However, clinical studies have found Xeomin to be safe and effective at doses up to 400 U in both previously treated and treatment-naïve patients. The recommended starting dose in patients with blepharospasm is 2.5-5.0 U/injection site. Patients can be switched using a 1:1 conversion ratio from Botox ® (onabotulinumtoxinA, Allergen Inc., Irvine, CA, USA) to Xeomin without any loss of efficacy or safety concerns. Xeomin does not differ from Botox in terms of its potency, onset, diffusion profile, or duration and waning of effect. It is the only botulinum treatment that is stable for up to 3 years at room temperature. Xeomin offers a new and important treatment option for movement disorders.

AB - Xeomin ® (incobotulinumtoxinA; Merz Pharmaceuticals, Frankfurt am Main, Germany) was first introduced in Germany for movement disorders in 2005. In 2010, it was approved for use in the United States by the FDA for the treatment of cervical dystonia (CD) and blepharospasm. It is a unique botulinum type A formulation free of any complexing proteins and contains only the pure 150 kD neurotoxin. Thus, the formation of neutralizing antibodies is not induced even after long-term treatment. The purpose of this report is to review the safety profile and dosing schedule for Xeomin for the treatment of CD and blepharospasm. The recommended dose for patients with CD is 120 U/treatment, with administration intervals normally between 3 and 6 months. However, clinical studies have found Xeomin to be safe and effective at doses up to 400 U in both previously treated and treatment-naïve patients. The recommended starting dose in patients with blepharospasm is 2.5-5.0 U/injection site. Patients can be switched using a 1:1 conversion ratio from Botox ® (onabotulinumtoxinA, Allergen Inc., Irvine, CA, USA) to Xeomin without any loss of efficacy or safety concerns. Xeomin does not differ from Botox in terms of its potency, onset, diffusion profile, or duration and waning of effect. It is the only botulinum treatment that is stable for up to 3 years at room temperature. Xeomin offers a new and important treatment option for movement disorders.

KW - Antibodies

KW - Complexing proteins

KW - Formulation

KW - Hemagglutinins

KW - Movement disorders

KW - Safety

UR - http://www.scopus.com/inward/record.url?scp=84861197172&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84861197172&partnerID=8YFLogxK

U2 - 10.1016/j.parkreldis.2012.02.008

DO - 10.1016/j.parkreldis.2012.02.008

M3 - Review article

C2 - 22405829

AN - SCOPUS:84861197172

SN - 1353-8020

VL - 18

SP - 441

EP - 445

JO - Parkinsonism and Related Disorders

JF - Parkinsonism and Related Disorders

IS - 5

ER -